Interleukin-16 deficiency suppresses the development of chronic rejection in murine cardiac transplantation model

IL-16-deficiency reduced graft inflammatory cell recruitment, and allograft inflammatory cytokine and chemokine production. Therefore, IL-16 neutralization may provide a potential target for novel therapeutic treatment for cardiac allograft rejection.